ChEBI logo

ChEBI


    The database and ontology of Chemical Entities of Biological Interest

spacer

everolimus (CHEBI:68478)

Search for only All in ChEBI

Main     ChEBI Ontology     Automatic Xrefs      
ChEBI Name everolimus
ChEBI ID CHEBI:68478
Definition A macrocyclic lactone that is rapamycin in which the hydroxy group attached to the cyclohexyl moiety has been converted to the corresponding 2-hydroxyethyl ether. It is an immunosuppressant and antineoplastic agent.
Stars This entity has been manually annotated by the ChEBI Team.
Supplier Information
See structure as:  Image  Applet
Save molfile Download Molfile
Wikipedia License
Waiting for wikipedia content
Read full article at Wikipedia
Formula Source
C53H83NO14 ChEBI
Net Charge 0
Average Mass 958.22440
InChI
InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1
InChIKey
HKVAMNSJSFKALM-GKUWKFKPSA-N
SMILES
[H][C@]1(CC[C@@H](OCCO)[C@@H](C1)OC)C[C@@H](C)[C@]1([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]2([H])CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@@]2([H])C(=O)O1)OC
Roles Classification
Chemical Role(s): mTOR inhibitor
A protein kinase inhibitor of the mammalian target of rapamycin (mTOR), a protein that regulates cell growth, cell proliferation, cell motility, cell survival, protein synthesis and transcription. mTOR inhibitors are used to prevent transplant rejection and in treatment of cancer.
Biological Role(s): immunosuppressive agent
An agent that suppresses immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-cells or by inhibiting the activation of helper cells. In addition, an immunosuppressive agent is a role played by a compound which is exhibited by a capability to diminish the extent and/or voracity of an immune response.
mTOR inhibitor
A protein kinase inhibitor of the mammalian target of rapamycin (mTOR), a protein that regulates cell growth, cell proliferation, cell motility, cell survival, protein synthesis and transcription. mTOR inhibitors are used to prevent transplant rejection and in treatment of cancer.
Application(s): immunosuppressive agent
An agent that suppresses immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-cells or by inhibiting the activation of helper cells. In addition, an immunosuppressive agent is a role played by a compound which is exhibited by a capability to diminish the extent and/or voracity of an immune response.
antineoplastic agent
A substance that inhibits or prevents the proliferation of neoplasms.
View more on the ChEBI Ontology
ChEBI Ontology
Outgoing everolimus (CHEBI:68478) has functional parent sirolimus (CHEBI:9168)
everolimus (CHEBI:68478) has role antineoplastic agent (CHEBI:35610)
everolimus (CHEBI:68478) has role immunosuppressive agent (CHEBI:35705)
everolimus (CHEBI:68478) has role mTOR inhibitor (CHEBI:68481)
everolimus (CHEBI:68478) is a cyclic acetal (CHEBI:59770)
everolimus (CHEBI:68478) is a cyclic ketone (CHEBI:3992)
everolimus (CHEBI:68478) is a ether (CHEBI:25698)
everolimus (CHEBI:68478) is a lactam (CHEBI:24995)
everolimus (CHEBI:68478) is a macrocyclic lactone (CHEBI:63944)
everolimus (CHEBI:68478) is a primary alcohol (CHEBI:15734)
everolimus (CHEBI:68478) is a secondary alcohol (CHEBI:35681)
IUPAC Name
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
INNs Sources
évérolimus WHO MedNet
everolimus WHO MedNet
everolimus WHO MedNet
everolimusum WHO MedNet
Synonyms Sources
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,35R)-1,18-dihydroxy-12-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone IUPAC
40-O-(2-hydroxyethyl)-rapamycin ChemIDplus
42-O-(2-Hydroxyethyl)rapamycin ChemIDplus
Everolimus ChemIDplus
Brand Name Source
Afinitor ChemIDplus
Database Links Databases
CN102138903 Patent
D02714 KEGG DRUG
DB01590 DrugBank
Everolimus Wikipedia
HMDB15529 HMDB
RU2008143550 Patent
WO2012066502 Patent
View more database links
Registry Number Type Source
159351-69-6 CAS Registry Number KEGG DRUG
Citations Waiting for Citations Types Sources
22404500 PubMed citation CiteXplore
22461124 PubMed citation CiteXplore
22683823 PubMed citation CiteXplore
22967800 PubMed citation CiteXplore
22969095 PubMed citation CiteXplore
22983698 PubMed citation CiteXplore
22986894 PubMed citation CiteXplore
Last Modified
29 January 2013

spacer
spacer